M&A Deal Summary |
|
---|---|
Date | 2010-11-08 |
Target | Avid Radiopharmaceuticals |
Sector | Life Science |
Buyer(s) | Lilly |
Sellers(s) |
Alta Partners
Safeguard |
Deal Type | Add-on Acquisition |
Deal Value | 300M USD |
Advisor(s) | Morgan Stanley (Financial) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1876 |
Sector | Life Science |
Employees | 43,000 |
Revenue | 34.1B USD (2023) |
Lilly discovers, develops, manufactures, and markets products in two business segments—human pharmaceutical products and animal health products. The mission of its human pharmaceutical business is to make medicines that help people live longer, healthier, more active lives. Most of the products Eli Lilly sells were discovered or developed by its own scientists, and the Company's success depends to a great extent on its ability to continue to discover, develop, and bring to market innovative new medicines. Eli Lilly's animal health business, operating through its Elanco division, develops, manufactures, and markets products for both food animals and companion animals. Eli Lilly manufactures and distributes its products through facilities in the US, Puerto Rico, and 11 other countries. Lilly was founded in 1876 and is based in Indianapolis, Indiana.
DEAL STATS | # |
---|---|
Overall | 15 of 34 |
Sector (Life Science) | 9 of 27 |
Type (Add-on Acquisition) | 13 of 27 |
State (Pennsylvania) | 1 of 1 |
Country (United States) | 14 of 29 |
Year (2010) | 2 of 2 |
Size (of disclosed) | 15 of 20 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2010-07-02 |
Alnara Pharmaceuticals
Cambridge, Massachusetts, United States Alnara Pharmaceuticals, Inc., a privately held biotechnology company developing protein therapeutics for the treatment of metabolic diseases. Alnara's lead product in development is liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT). Liprotamase is under review by the U.S. Food and Drug Administration for the treatment of exocrine pancreatic insufficiency (EPI). Causes of EPI include cystic fibrosis, chronic pancreatitis, pancreatectomy and other conditions. |
Buy | $180M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2013-04-17 |
Siemens Medical Solutions - Two Investigational Positron
United States Siemens Medical Solutions - Two Investigational Positron Emission Tomography (PET) Tracers comprises two investigational positron emission tomography (PET) tracers, intended to image the neurofibrillary tangles in the brain for the diagnostics of Alzheimer's disease. |
Buy | - |
Category | Venture Capital Firm |
---|---|
Founded | 1996 |
PE ASSETS | 2.6B USD |
Size | Large |
Type | Sector Focused |
Alta Partners is a venture capital firm that targets investments in early and later stage life science companies, including biopharmaceuticals, medical technology, and information technology businesses. Alta was formed as an early stage investor but has since expanded its investment range to provide later stage growth capital to private and young public companies. Alta was established in 1996 and is headquartered in San Francisco, California.
DEAL STATS | # |
---|---|
Overall | 46 of 84 |
Sector (Life Science) | 31 of 64 |
Type (Add-on Acquisition) | 31 of 45 |
State (Pennsylvania) | 2 of 4 |
Country (United States) | 39 of 74 |
Year (2010) | 5 of 5 |
Size (of disclosed) | 13 of 23 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2010-10-22 |
Aegerion Pharmaceuticals
Cambridge, Massachusetts, United States Aegerion Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of pharmaceutical products to treat cardiovascular and metabolic diseases. Aegerion Pharmaceuticals, Inc. was formed in 2005 and is headquartered in Cambridge, Massachusetts. |
Sell | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2011-01-31 |
Taligen Therapeutics
Cambridge, Massachusetts, United States Taligen is a development stage biotechnology company focused on the treatment of serious inflammatory diseases including asthma, macular degeneration and immune kidney disease. |
Sell | $111M |
Category | Company |
---|---|
Sector | Financial Services |
Employees | 30 |
Revenue | 6M USD (2023) |
Safeguard is a provider of capital and operational expertise to emerging and growth-stage healthcare and technology enterprises that are developing innovative products and services.
DEAL STATS | # |
---|---|
Overall | 2 of 9 |
Sector (Life Science) | 1 of 3 |
Type (Add-on Acquisition) | 1 of 3 |
State (Pennsylvania) | 1 of 3 |
Country (United States) | 2 of 9 |
Year (2010) | 1 of 1 |
Size (of disclosed) | 2 of 6 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2008-09-16 |
NextPoint Networks
Gaithersburg, Maryland, United States NextPoint Networks, Inc. is a provider of security solutions, including Session Border Controllers (SBC) and Security Gateways (SeG) for Fixed Mobile Convergence (FMC) solutions. |
Sell | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2011-02-16 |
ThingWorx
Exton,, Pennsylvania, United States ThingWorx, Inc. is a provider of platform for building and running applications for the Internet of Things (IoT). |
Buy | - |